Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th

Jyong Biotech’s (NASDAQ:MENS) lock-up period will end on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its public offering on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Jyong Biotech Price Performance

Shares of NASDAQ MENS opened at $29.20 on Monday. The firm’s fifty day moving average is $43.41. Jyong Biotech has a 52-week low of $6.01 and a 52-week high of $67.00.

Institutional Trading of Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets bought a new stake in Jyong Biotech Ltd. (NASDAQ:MENS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,698 shares of the company’s stock, valued at approximately $67,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.